Health Canada authorizes Novavax COVID-19 vaccine for individuals 18 years of age and older.
Novavax announced on Feb. 17, 2022 that Health Canada has granted authorization for Nuvaxovid COVID-19 Vaccine for individuals 18 years of age and older. The vaccine provides active immunization to prevent COVID-19 caused by SARS-CoV-2. Nuvaxovid is the first protein-based vaccine to be authorized for use in Canada.
“We are proud that Canada is part of the growing list of regions to authorize Nuvaxovic and that Canadians will have a protein-based COVID-19 vaccine option,” stated Stanley C. Erck, president and chief executive officer of Novavax, in a press release. “We thank the Canadian government and the National Research Council of Canada for their ongoing partnership and commitment to helping combat the evolving pandemic.”
In January 2021, Novavax and the Government of Canada signed an advance purchase agreement for 52 million doses of Novavax’ COVID-19 vaccine, with the option for up to an additional 24 million doses. Novavax also established a memorandum of understanding to produce the vaccine at the National Research Council of Canada’s Biologics Manufacturing Centre in Montréal in February 2021. Production is expected to begin later this year.
Source: Novavax
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
A Novel, Enhanced, and Sustainable Approach to Audit Trail Review
July 4th 2025Eli Lilly and Company developed an innovative and sustainable approach to audit trail review (ATR) aimed at reducing the ATR burden while adhering to regulatory expectations and data integrity (DI) principles. The process has transformed employees' understanding of ATR and complemented the DI by design approach, leading to better system designs that meet expected controls and reduce non-value-added data reviews.
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
A Novel, Enhanced, and Sustainable Approach to Audit Trail Review
July 4th 2025Eli Lilly and Company developed an innovative and sustainable approach to audit trail review (ATR) aimed at reducing the ATR burden while adhering to regulatory expectations and data integrity (DI) principles. The process has transformed employees' understanding of ATR and complemented the DI by design approach, leading to better system designs that meet expected controls and reduce non-value-added data reviews.
2 Commerce Drive
Cranbury, NJ 08512